Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Recruitment & Eligibility

Status: Active, not recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria: - Male and female participants aged = 12 to < 18 years at the time of signing the informed consent. - All study participants must be diagnosed with (i) NF1 per NIH Consensus Development Conference Statement and (ii) inoperable PN. In addition to PN, participants must have at least 1 other diagnostic criterion for NF1 as defined in protocol. - Participants must require treatment for NF1 and inoperable PN due to actual symptoms or because of the potential to develop significant clinical complications, as judged by the Investigator, as defined in the protocol. - Participants who have had prior treatment with any MEKi (including selumetinib) may be considered for inclusion in this study. - Participants must have a BSA = 1.3 and = 2.5 m2 Exclusion Criteria: - Evidence or suspicion of optic glioma, malignant glioma, MPNST, or other cancer requiring treatment with chemotherapy or radiation therapy - Prior malignancy requiring active treatment (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the participant had been disease free for = 2 years or which would not have limited survival to < 2 years). - A life-threatening illness, medical condition, organ system dysfunction of laboratory finding which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of selumetinib, or put the study outcomes at undue risk. - Participants with clinically significant cardiovascular disease as listed in the protocol. - Liver function tests: bilirubin > 1.5 × the ULN for age (with the exception of those with Gilbert syndrome) or AST/ALT > 2 × upper limit of normal. - Renal Function: Creatinine clearance or radioisotope glomerular filtration rate < 30 mL/min/1.73 m2 or a serum creatinine > 1.2 mg/dL (for participants aged between 12 and 15 years) or > 1.5 mg/dL for participants aged > 15 years). - Participants with abnormal ophthalmological findings/conditions as listed in the protocol. - Have any unresolved chronic toxicity, associated with previous therapy for NF1-PN: Gastrointestinal toxicity of CTCAE Grade 1 or higher; Have any other unresolved chronic toxicity with CTCAE Grade = 2, except hair changes (such as alopecia or hair lightening). - Participants who have previously been treated with a MEKi (including selumetinib) and either discontinued treatment or required a dose reduction due to toxicity - Have had recent major surgery within a minimum of 4 weeks prior to starting study intervention, with the exception of surgical placement for vascular access. Have planned major surgery during the treatment period. - Any multivitamin containing vitamin E must be stopped at least 7 days prior to initiation of selumetinib.

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Selumetinib area under the plasma concentration-time curve from zero to 12 hours post-dose (AUC0-12);Gastrointestinal Adverse Events graded by CTCAE Ver 5.0 (Grade 1 to 5);Assessing change of Gastrointestinal toxicity diary: Modified Bristol Stool Form Scale for Children (mBSFS-C);Assessing change of Gastrointestinal toxicity diary: Nausea and Vomiting Symptom Rating Scale (adapted from the Children's Cancer and Leukaemia Group);Number of patients who take each gastrointestinal medication;Proportion of patients who take each gastrointestinal medication

Secondary Outcome Measures

Name	Time	Method
Adverse events(AEs) graded by CTCAE Version 5.0;Maximum Peak plasma concentration (Cmax) of selumetinib and N-desmethyl selumetinib;Area under the concentration-time curve from time zero to time of last measurable concentration (AUClast) of selumetinib and N-desmethyl selumetinib;Time to maximum concentration (tmax) of selumetinib and N-desmethyl selumetinib;Time to last measurable concentration (tlast) of selumetinib and N-desmethyl selumetinib

Updated 3/2/2022

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Recruitment & Eligibility

Study & Design

Related Trials

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

Phase I Study to Assess the Effect of Food on the PK and GastrointestinalTolerability of Selumetinib in Adolescent Children with NeurofibromatosisType 1 (NF1) Related Plexiform Neurofibromas (PN)

Clinical research of filling extraction sockets with selective COX2 inhibitor-containing paste in patients with mandibular wisdom tooth extractions.

A Phase I/II, Single-Arm, Open-label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged >= 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)

A single-centre, open-label, phase I study to evaluate the diagnostic performance of 89Zirconium-labelled girentuximab (89Zr-TLX250) Position Emission Tomography (PET) in Urothelial Cancer Patients

A phase I, open-label, single-centre study to evaluate the absorption, distribution, metabolism and excretion (ADME) of oral [14C]-ibrexafungerp in healthy male subjects after repeat dosing

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged 1 or more to < 7 Years with NF1-related Symptomatic, Inoperable PN (SPRINKLE).

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged = 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged = 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged = 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)

Clinical Trial Alerts

Clinical Trial Alerts